Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

Executive Leadership Changes - John Crowley CPA has been appointed as the new Chief Financial Officer (CFO) of Centessa Pharmaceuticals, bringing over 20 years of global finance and operational experience in the life sciences industry [5][9] - Gregory Weinhoff MD MBA, the former CFO, has been appointed to the newly created role of Chief Business Officer (CBO), leveraging his extensive business development experience [5][6] - John Crowley's previous roles include CFO at Fusion Pharmaceuticals, Executive Vice President and CFO at Merus Inc, and senior corporate finance positions at Charles River Laboratories, Ironwood Pharmaceuticals, Vertex Pharmaceuticals, and Sunovion Pharmaceuticals [9] - Gregory Weinhoff has over 20 years of business development experience, including roles as CFO at Centessa and Axovant Sciences, and co-founder of Arvelle Therapeutics, which was acquired by Angelini Pharma in 2021 [3] Company Overview and Strategic Focus - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients [7] - The company's most advanced programs include a hemophilia program, an orexin agonist program for narcolepsy and sleep-wake disorders, and an immuno-oncology program based on the LockBody® technology platform [7] - The company believes its programs have the potential to change current treatment paradigms and establish new standards of care [7] - Centessa has strengthened its leadership team to position the company for its next phase of growth, with a focus on advancing its clinical programs and maintaining a strong financial framework [1] Business Development and Financial Strategy - The appointment of John Crowley as CFO is expected to enhance the company's financial strategy, operations, and planning, given his deep technical knowledge and experience in the life sciences industry [1][9] - Gregory Weinhoff's new role as CBO will focus on leveraging his experience in developing strategic industry partnerships to bring transformative medicines to patients [6] - The company has emphasized the importance of business development and financial strategy as it transitions into its next chapter of growth [1][6]